Published in Drug Week, January 14th, 2005
PEG-INTRON and REBETOL are marketed worldwide by Schering-Plough Corporation (NYSE: SGP).
PEG-INTRON and REBETOL combination therapy is the first and only pegylated interferon-based combination therapy approved in Japan. An estimated 1 to 2 million Japanese are chronically infected with hepatitis C. PEG-INTRON is a longer-acting form of INTRON A (interferon alfa-2b, recombinant) Injection that uses proprietary PEG technology developed by Enzon. Under the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.